||COM SHS USD0.001 (REGS)
||EPS - Basic
||Market Cap (m)
|Pharmaceuticals & Biotechnology
Real-Time news about Northw.Bio Regs (London Stock Exchange): 0 recent articles
|andrbea: interesting to see the latent effect of a new drug for prostrate cancer would have on a share price
compare this story from March 2007
caused a 250% pre-market spike...
|andrbea: While there has been tremendous hype and controversy surrounding companies developing cancer vaccines, including Dendreon (DNDN) and Cell Genesys (CEGE), a tiny Swiss biotech company took center stage on Monday. Northwest BioTherapeutics (NWBO.OB) announced that the Swiss Institute of Public Health had cleared its dendretic-cell vaccine, DCVax®-Brain, for commercial launch for treatment of brain cancer
So, it is possible that the company will produce the vaccine in the U.S., and end up selling it to Americans in Switzerland, at much higher prices! The company is currently conducting Phase II trials in both the U.S. and EU, but expects final results by end of 2008.
The company is also cleared to investigate its DCVax® Technology platform in various other cancers, including a phase III trial for prostate cancer. This should make Dendreon investors a little nervous. The company's DCVax® Technology has tremendous advantages over competing cancer vaccine platforms.
Even following Monday's jump in share price, the company still has a tiny market cap of only $32 million. If you thought Dendreon shares are wild, think again!
Northw.Bio Regs share price data is direct from the London Stock Exchange